An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid

Trial Profile

An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Bertilimumab (Primary)
  • Indications Bullous pemphigoid
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immune Pharmaceuticals Inc
  • Most Recent Events

    • 27 Sep 2017 Preliminary results from the first six subjects presented in an Immune Pharmaceuticals Media Release.
    • 28 Aug 2017 According to an Immune Pharmaceuticals Inc media release, the orphan drug designation application for bertilimumab in Bullous Pemphigoid was filed in February 2017.
    • 04 Aug 2017 According to an Immune Pharmaceuticals Inc media release, preliminary data from this trial were presented at the American Academy of Dermatology 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top